With 1,000 Enrolled, Iverson Hoping to Report First Warfarin PGx Study Outcomes Data by End of 2015 | GenomeWeb

This article has been updated from an earlier version with additional information about the design and size of the WARFARIN trial. Additionally, Iverson has further clarified the difference between its study and the COAG trial.

MOUNTAIN VIEW, Calif. – By the end of 2015, Iverson Genetics is hoping to report final data from a large-scale prospective trial to determine whether genetic testing helps patients avoid serious adverse events associated with the highly variable anticoagulant warfarin.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.